Synergistic up-regulation of vascular endothelial growth factor expression in murine macrophages by adenosine A(2A) receptor agonists and endotoxin

Am J Pathol. 2002 Jun;160(6):2231-44. doi: 10.1016/S0002-9440(10)61170-4.

Abstract

Under normoxic conditions, macrophages from C57BL mice produce low levels of vascular endothelial growth factor (VEGF). Hypoxia stimulates VEGF expression by approximately 500%; interferon-gamma (IFN-gamma) with endotoxin [lipopolysaccharide (LPS)] also stimulates VEGF expression by approximately 50 to 150% in an inducible nitric oxide synthase (iNOS)-dependent manner. Treatment of normoxic macrophages with 5'-N-ethyl-carboxamido-adenosine (NECA), a nonselective adenosine A(2) receptor agonist, or with 2-[p-(2-carboxyethyl)-phenylethyl amino]-5'-N-ethyl-carboxamido-adenosine (CGS21680), a specific adenosine A(2A) receptor agonist, modestly increases VEGF expression, whereas 2-chloro-N(6)-cyclopentyl adenosine (CCPA), an adenosine A(1) agonist, does not. Treatment with LPS (0 to 1000 ng/ml), or with IFN-gamma (0 to 300 U/ml), does not affect VEGF expression. In the presence of LPS (EC(50) < 10 ng/ml), but not of IFN-gamma, both NECA and CGS21680 synergistically up-regulate VEGF expression by as much as 10-fold. This VEGF is biologically active in vivo in the rat corneal bioassay of angiogenesis. Inhibitors of iNOS do not affect this synergistic induction of VEGF, and macrophages from iNOS-/- mice produce similar levels of VEGF as wild-type mice, indicating that NO does not play a role in this induction. Under hypoxic conditions, VEGF expression is slightly increased by adenosine receptor agonists but adenosine A(2) or A(1) receptor antagonists 3,7-dimethyl-1-propargyl xanthine (DMPX), ZM241385, and 8-cyclopentyl-1,3-dipropylxanthine (DCPCX) do not modulate VEGF expression. VEGF expression is also not reduced in hypoxic macrophages from A(3)-/- and A(2A)-/- mice. Thus, VEGF expression by hypoxic macrophages does not seem to depend on endogenously released or exogenous adenosine. VEGF expression is strongly up-regulated by LPS/NECA in macrophages from A(3)-/- but not A(2A)-/- mice, confirming the role of adenosine A(2A) receptors in this pathway. LPS with NECA strongly up-regulates VEGF expression by macrophages from C(3)H/HeN mice (with intact Tlr4 receptors), but not by macrophages from C(3)H/HeJ mice (with mutated, functionally inactive Tlr4 receptors), implicating signaling through the Tlr4 pathway in this synergistic up-regulation. Finally, Western blot analysis of adenosine A(2A) receptor expression indicated that the synergistic interaction of LPS with A(2A) receptor agonists does not involve up-regulation of A(2A) receptors by LPS. These results indicate that in murine macrophages there is a novel pathway regulating VEGF production, that involves the synergistic interaction of adenosine A(2A) receptor agonists through A(2A) receptors with LPS through the Tlr4 pathway, resulting in the strong up-regulation of VEGF expression by macrophages in a hypoxia- and NO-independent manner.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adenosine / analogs & derivatives*
  • Adenosine / pharmacology
  • Adenosine-5'-(N-ethylcarboxamide) / pharmacology
  • Animals
  • Blotting, Western
  • Cells, Cultured
  • Drosophila Proteins*
  • Endothelial Growth Factors / biosynthesis*
  • Female
  • Interferon-gamma / pharmacology
  • Lipopolysaccharides / pharmacology*
  • Lymphokines / biosynthesis*
  • Macrophages, Peritoneal / drug effects
  • Macrophages, Peritoneal / metabolism*
  • Male
  • Membrane Glycoproteins / physiology*
  • Mice
  • Mice, Inbred C3H
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Nitric Oxide / physiology
  • Nitric Oxide Synthase / physiology
  • Nitric Oxide Synthase Type II
  • Phenethylamines / pharmacology
  • Protein Kinase Inhibitors
  • Purinergic P1 Receptor Agonists*
  • RNA, Messenger / metabolism
  • Receptor, Adenosine A2A
  • Receptors, Cell Surface / physiology*
  • Receptors, Purinergic P1 / physiology
  • Reverse Transcriptase Polymerase Chain Reaction
  • Signal Transduction*
  • Theobromine / analogs & derivatives*
  • Theobromine / pharmacology
  • Toll-Like Receptor 4
  • Toll-Like Receptors
  • Triazines / pharmacology
  • Triazoles / pharmacology
  • Up-Regulation*
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors
  • Xanthines / pharmacology

Substances

  • Drosophila Proteins
  • Endothelial Growth Factors
  • Lipopolysaccharides
  • Lymphokines
  • Membrane Glycoproteins
  • Phenethylamines
  • Protein Kinase Inhibitors
  • Purinergic P1 Receptor Agonists
  • RNA, Messenger
  • Receptor, Adenosine A2A
  • Receptors, Cell Surface
  • Receptors, Purinergic P1
  • Toll-Like Receptor 4
  • Toll-Like Receptors
  • Triazines
  • Triazoles
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors
  • Xanthines
  • ZM 241385
  • 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine
  • Nitric Oxide
  • Adenosine-5'-(N-ethylcarboxamide)
  • 2-chloro-N(6)cyclopentyladenosine
  • 3,7-dimethyl-1-propargylxanthine
  • Interferon-gamma
  • 1,3-dipropyl-8-cyclopentylxanthine
  • Nitric Oxide Synthase
  • Nitric Oxide Synthase Type II
  • Nos2 protein, mouse
  • Adenosine
  • Theobromine